Cure My Disease

Don't miss your cure!

 Log in / Sign up

Ultrasound and blood markers may unlock personalized treatment for rare nerve disease

NCT ID NCT07719153

Not yet recruiting Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Nice Source: ClinicalTrials.gov ↗

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This study investigates whether nerve ultrasound patterns and biomarkers in blood and spinal fluid can predict how people with chronic inflammatory demyelinating polyneuropathy (CIDP) respond to treatment. Researchers will follow 30 adults with CIDP, including newly diagnosed and treatment-resistant cases, to see if imaging and lab results match clinical outcomes. The goal is to develop a strategy for more personalized care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this could lead to a way to predict which CIDP patients will respond to standard treatments, enabling more personalized and effective care.
What could go wrong
This is a small, early observational study, so findings may not apply to all CIDP patients. It is not testing a new treatment, only exploring potential markers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC INFLAMMATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic inflammatory demyelinating polyradiculoneuropathy demyelinating polyneuropathy polyneuropathy, inflammatory demyelinating, chronic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC INFLAMMATION CIDP DEMYELINATING POLYNEUROPATHY

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.